Pharvaris (NASDAQ:PHVS) Rating Lowered to “Sell” at Wall Street Zen

Pharvaris (NASDAQ:PHVS) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Sunday.

Several other research firms also recently commented on PHVS. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Pharvaris in a report on Tuesday, March 3rd. Royal Bank Of Canada started coverage on shares of Pharvaris in a report on Monday, March 9th. They issued an “outperform” rating and a $52.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Thursday, January 22nd. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $41.60.

Pharvaris Price Performance

NASDAQ:PHVS opened at $28.37 on Friday. Pharvaris has a one year low of $11.51 and a one year high of $29.85. The company has a market cap of $1.54 billion, a P/E ratio of -8.42 and a beta of -2.58. The firm’s fifty day moving average price is $27.07 and its two-hundred day moving average price is $25.47.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors have recently modified their holdings of the business. General Atlantic L.P. boosted its position in shares of Pharvaris by 6.6% in the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after acquiring an additional 500,000 shares during the period. Foresite Capital Management IV LLC boosted its position in shares of Pharvaris by 8.3% in the third quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after acquiring an additional 368,000 shares during the period. venBio Partners LLC boosted its position in shares of Pharvaris by 8.2% in the third quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after acquiring an additional 350,000 shares during the period. Deerfield Management Company L.P. boosted its position in shares of Pharvaris by 21.1% in the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock valued at $60,939,000 after acquiring an additional 425,000 shares during the period. Finally, Commodore Capital LP boosted its position in shares of Pharvaris by 26.5% in the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after acquiring an additional 507,043 shares during the period.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.